Table 2

Chemotherapy Associated With Ischemia

Chemotherapy AgentsIncidence (%)Frequency of Use
Antimetabolites
 Capecitabine (Xeloda) (71,74,83–85)3–9+++
 Fluorouracil (Adrucil) (8,70,71,73–79)1–68+++
Antimicrotubule agents
 Paclitaxel (Taxol) (90,91)<1–5+++
 Docetaxel (Taxotere) (10,92)1.7++
Monoclonal antibody-based tyrosine kinase inhibitor
 Bevacizumab (Avastin) (10,93,94)0.6–1.5++
Small molecule tyrosine kinase inhibitors
 Erlotinib (Tarceva) (10)2.3+++
 Sorafenib (Nexavar) (10,96)2.7–3+++

For an explanation of the + symbols, please see Table 1.

  • The incidence of ischemia varies widely in the literature for 5-fluorouracil due to the differences in study design, definition of ischemia, and numbers of patients. Medication manufacturers and locations: Xeloda, Roche Laboratories Inc., Nutley, New Jersey; Adrucil, Sicor Pharmaceuticals, Irvine, California; Taxol, Bristol-Myers Squibb, Princeton, New Jersey; Tarceva, OSI Pharmaceuticals Inc., Melville, New York; Nexavar, Bayer HealthCare Pharmaceuticals, Inc., Wayne, New Jersey; see Table 1for others.